Control of Gemcitabine Activity With Blue and Red Light.

Area of Science:

• Medicinal Chemistry
• Photochemistry
• Oncology

Background:

• Chemotherapy for cancer treatment often causes severe side effects.
• Selective drug delivery can mitigate these adverse effects.
• Photoremovable protecting groups (PPGs) offer a method for light-triggered drug release.

Purpose of the Study:

• To synthesize and evaluate novel light-activatable cytostatics for targeted cancer therapy.
• To develop chemotherapy drugs with reduced toxicity in the absence of light.
• To investigate the potential of photopharmacology in cancer treatment.

Main Methods:

• Synthesis of sixteen new light-activatable cytostatics using photoremovable protecting groups (PPGs), including a blue light-activatable diethylaminocoumarin (DEACM) group.
• Photochemical property testing of synthesized compounds.
• Cytotoxicity studies using HT-29 colon cancer cells to assess drug activity and light-dependent release.
• Design and synthesis of a red-light activatable gemcitabine derivative (gem-Cy-tabine) using a heptamethine (Cy7) PPG.

Main Results:

• The DEACM-gemcitabine derivative demonstrated full gemcitabine activity recovery post-irradiation and was 29 times less toxic without blue light.
• The red-light activatable gem-Cy-tabine showed minimal activity without red light, with activity increasing over 33-fold after irradiation.
• Photorelease of gemcitabine was confirmed in HT-29 cells using tissue-penetrating red light.

Conclusions:

• Novel light-activatable cytostatics, particularly gemcitabine derivatives, show promise for targeted cancer therapy.
• The developed red-light activatable gem-Cy-tabine offers a potential strategy for photopharmacology with enhanced specificity and reduced systemic toxicity.
• Further investigation into these photopharmacological agents could lead to more precise and effective cancer treatments.